D011719Chemicals & DrugsD03.383.6799110.995458PyrazinesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonStefanGrantStefan C. Grant JD, MD36.09103700000000-80.269096000000001728Grant, StefanProfessorCancer BiologyWake Forest School of MedicineGlennLesserGlenn J. Lesser MD36.08919100000000-80.26677800000000315Lesser, GlennProfessorWilliamGmeinerWilliam H. Gmeiner PhD36.09032400000000-80.2664910000000080Gmeiner, WilliamProfessorXinMingXin Ming PhD36.09032400000000-80.266491000000002029Ming, XinAssociate ProfessorCaio MaxRocha LimaCaio Max S. Rocha Lima MD, MS2211Rocha Lima, Caio MaxProfessor29643063Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell JClinical cancer research : an official journal of the American Association for Cancer ResearchHong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.Clin Cancer Res2018-04-11T00:00:002018Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.22144178Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MABloodMannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood. 2012 Feb 09; 119(6):1450-8.Blood2011-12-05T00:00:002011KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.29361039Juliano RL, Wang L, Tavares F, Brown EG, James L, Ariyarathna Y, Ming X, Mao C, Suto MNucleic acids researchJuliano RL, Wang L, Tavares F, Brown EG, James L, Ariyarathna Y, Ming X, Mao C, Suto M. Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides. Nucleic Acids Res. 2018 02 28; 46(4):1601-1613.Nucleic Acids Res2018-02-28T00:00:002018Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides.20Professor22Associate Professor31492187Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle KBreast cancer research : BCRMani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2019 09 06; 21(1):104.Breast Cancer Res2019-09-06T00:00:002019Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.Internal Medicine, Hematology & Oncology32338136Reed DR, Sen JM, Pierce EJ, Elsarrag RZ, K Keng MJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersReed DR, Sen JM, Pierce EJ, Elsarrag RZ, K Keng M. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. J Oncol Pharm Pract. 2020 Jul; 26(5):1200-1212.J Oncol Pharm Pract2020-04-26T00:00:002020Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor0.1824090.02839699research area of0.7661010.070584521subject area for